Core Insights - Xellar Biosystems, a technology platform focused on "AI + organ-on-a-chip" integration, has completed a new round of strategic financing amounting to tens of millions of yuan, led by XtalPi, a global leader in AI drug and new materials research [1] - The funding will accelerate the development of its "3D-Wet-AI" closed-loop system, which integrates organ-on-a-chip technology, wet lab capabilities, and AI algorithms, while also expanding international collaborations and commercial applications [1][2] - Xellar Biosystems aims to redefine drug development, safety evaluation, and precision medicine processes through its self-developed high-throughput organ-on-a-chip and AI model platform [1][4] Investment and Collaboration - The strategic investment from XtalPi will facilitate deep collaboration on high-quality biological data generation, complex disease modeling, AI-assisted toxicology predictions, and drug efficacy extrapolation [2] - The partnership aims to integrate organ-on-a-chip technology with automation, creating a seamless connection between in vitro complex models and AI molecular generation and screening algorithms [2][5] - This collaboration is expected to enhance drug development efficiency and success rates by providing clinically relevant research data [2][3] Regulatory Landscape - Global regulatory bodies are accelerating the transition away from animal testing, with the FDA Modernization Act 2.0 allowing non-animal methods for new drug IND submissions [3] - The FDA is launching multiple multi-center validation projects from 2023 to 2025 to incorporate organ-on-a-chip and human cell models into mainstream toxicology and efficacy evaluation standards [3] - Xellar Biosystems is actively participating in standard validation with regulatory agencies, providing safety and efficacy analysis services to pharmaceutical companies and research institutions [3] Technological Advancements - Xellar's EPIC platform combines microfluidic chip technology, disease modeling, high-throughput experimental systems, and generative AI algorithms, enabling rapid construction of complex microenvironments and multi-dimensional imaging [4] - The platform has been utilized in early drug toxicity prediction, functional food and skincare product screening, and personalized treatment response simulation [4] - The integration of AI and organ-on-a-chip technology is seen as a transformative shift in life sciences, enhancing the entire research and development logic [4][5] Market Position and Future Outlook - Xellar Biosystems is positioned as a key player in the AI + organ-on-a-chip sector, with strong technical execution and industry sensitivity demonstrated over the past two years [5][6] - The collaboration with XtalPi is viewed as a significant step in reinforcing Xellar's leading position in the AI + organ-on-a-chip integration path [5] - The focus on high-quality physiological data generation and deep coupling with AI models is expected to drive innovation in biomedicine, enhancing decision-making across regulatory, industrial, and consumer scenarios [6]